La cadena de opciones muestra datos clave de las opciones de acciones de West Pharmaceutical Servs a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para West Pharmaceutical Servs..

West Pharmaceutical Servs (NYSE:WST) Bolsa, Cadena de Opciones

West Pharmaceutical Servs

West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AMOD

DGLY

EDSA

El Índice de Precios al Productor en EE. UU. subió un 3,5% en enero, superando las previsiones. ¿Cómo reaccionaron los mercados?

Acciones de EE. UU. reaccionan al alza tras el aumento del PPI: ¿qué esperar ahora?

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Services Inc

WEST HOLDINGS CORP by West Holdings Corp.

West Holdings Corp

WESTELL TECHS INC A NEW by Westell Technologies, Inc.

Westell Technologies Inc

WESTERN URANIUM&VANADIUM by Western Uranium & Vanadium Corp.

Western Uranium & Vanadium Corp

WESTPORTS HLDGS BHD ORD by WESTPORTS HLDGS BHD

Westports Holdings Bhd

Wrapped stETH - United States Dollar

These ten large-cap stocks were top performers last week. Are they a&nbsp;<a href="https://www.benzinga.com/trading-ideas" target="_blank" rel="noreferrer noopener">part of your portfolio</a>?
1. Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) gained over 137.10% in the last week after the company reported second-quarter earnings per share of $3.10, <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46550726/medspace-stock-is-trading-higher-tuesday-whats-going-on" target="_blank" rel="noreferrer noopener">beating the consensus estimate of $2.97.</a>
2. ICON plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) increased 30.28% last weekl after the company reported better-than-expected&nbsp;second-quarter&nbsp;financial results and raised its&nbsp;<a href="https://www.benzinga.com/markets/earnings/25/07/46612555/icon-stock-up-after-q2-results-signal-growing-confidence-in-biopharma-recovery" target="_blank" rel="noreferrer noopener">fiscal 2025 sales&nbsp;guidance.</a>
3. West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) jumped 24.96% this week after the injectable pharmaceutical packaging and delivery systems company delivered a robust beat on its&nbsp;second-quarter 2025&nbsp;earnings and revenue, while also significantly <a href="https://www.benzinga.com/markets/earnings/25/07/46604599/west-pharma-lifts-outlook-on-surging-glp-1-demand-stock-soars" target="_blank" rel="noreferrer noopener">raising its full-year guidance</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/etfs/sector-etfs/25/07/46648142/palantir-nvidia-tempus-ai-could-be-pharma-etf-darlings-that-dont-make-pills" rel="noreferrer noopener">Palantir, Nvidia &amp; Tempus AI Could Be Pharma ETF Darlings That Don&#8217;t Make Pills</a>
4. Comfort Systems USA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) gained 24.46% the last week after the company reported better-than-expected Q2 financial results and raised its quarterly <a href="https://www.benzinga.com/pressreleases/25/07/b46616670/comfort-systems-usa-reports-second-quarter-2025-results" target="_blank" rel="noreferrer noopener">dividend from $0.45 to $0.50 per share.</a>
5. IQVIA Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) jumped 23.5% this week after&nbsp;the company reported better-than-expected Q2 financial results and issued FY25 sales<a href="https://www.benzinga.com/pressreleases/25/07/b46539884/iqvia-reports-second-quarter-2025-results" target="_blank" rel="noreferrer noopener"> guidance above estimates.</a>
6. Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) increased 10.18% this week. Jefferies analyst Blayne Curtis maintains Astera Labs with a Buy rating and raises the <a href="https://www.benzinga.com/news/25/07/46520572/galaxy-digital-blaize-holdings-verizon-and-other-big-stocks-moving-higher-on-monday" target="_blank" rel="noreferrer noopener">price forecast from&nbsp;$95&nbsp;to&nbsp;$130.</a>
7. TE Connectivity plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>)&nbsp;shares gained 16.72% after the company reported better-than-expected third-quarter<a href="https://www.benzinga.com/markets/market-summary/25/07/46583497/markets-today-trade-deals-trump-japan-eu-wall-street-stocks" target="_blank" rel="noreferrer noopener"> adjusted EPS and sales.</a>
8. Baker Hughes Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) increased 14.98% after the company reported<a href="https://www.benzinga.com/pressreleases/25/07/g46560108/baker-hughes-company-announces-second-quarter-2025-results" target="_blank" rel="noreferrer noopener"> better-than-expected Q2 financial results.</a>
9. Thermo Fisher Scientific Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) stock gained 16.72% after the company reported <a href="https://www.benzinga.com/pressreleases/25/07/b46566528/thermo-fisher-scientific-reports-second-quarter-2025-results" target="_blank" rel="noreferrer noopener">better-than-expected Q2 financial results.</a> Baird maintained an Outperform rating on the stock and raised its price target from $553 to $567. Also, Barclays raised its price target on the stock from $450 to $490.
10. Deckers Outdoor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) stock gained 12.15% this week after it reported <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46635898/deckers-outdoor-wholesale-drives-q1-beat-tariff-pressure-worries-analysts" target="_blank" rel="noreferrer noopener">better-than-expected Q1 financial results.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/financial-advisors/25/07/46646681/warren-buffett-issues-urgent-warning-on-looming-social-security-cuts" target="_blank" rel="noreferrer noopener">Warren Buffett Issues Urgent Warning On Looming Social Security Cuts</a></li>
</ul>

Movers

General

ALAB

DECK

ICLR

MEDP

Thermo Fisher, Baker Hughes And IQVIA Holdings Are Among Top 10 Large Cap Gainers Last Week (July 21-July 25): Are The Others In Your Portfolio?

UBS analyst John Sourbeer maintains West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) with a Buy and raises the price target from $285 to $320.

Price Target

Analyst Ratings

UBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $320

Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) with a Outperform and raises the price target from $275 to $350.

Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $350

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock rose 74.6% to $0.04 during Thursday's regular session. The market value of their outstanding shares is at $10.2 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock moved upwards by 41.51% to $0.69. The company's market cap stands at $24.9 million. </li>
<li>X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) stock increased by 31.25% to $1.97. The company's market cap stands at $10.7 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock increased by 30.6% to $8.45. The market value of their outstanding shares is at $170.5 million. </li>
<li>West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) shares increased by 20.77% to $274.53. The company's market cap stands at $16.3 billion. The company's, Q2 earnings came out today. </li>
<li>Sensus Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) shares moved upwards by 19.49% to $5.64. The market value of their outstanding shares is at $77.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) stock decreased by 27.6% to $2.81 during Thursday's regular session. The market value of their outstanding shares is at $544.3 million. As per the press release, Q2 earnings came out yesterday. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock decreased by 19.15% to $1.52. The market value of their outstanding shares is at $10.0 million. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares fell 18.51% to $10.86. The company's market cap stands at $1.3 billion. </li>
<li>NovoCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) stock declined by 16.84% to $13.73. The company's market cap stands at $1.8 billion. As per the press release, Q2 earnings came out today. </li>
<li>Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) stock decreased by 15.24% to $3.37. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) shares fell 14.41% to $5.11. The market value of their outstanding shares is at $6.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLM

HCTI

IOVA

LIMN

NVCR

PLRZ

PSTV

SRPT

SRTS

XFOR

12 Health Care Stocks Moving In Thursday's Intraday Session

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 200 points on Thursday.
The Dow traded down 0.51% to 44,779.97 while the NASDAQ rose 0.11% to 21,044.05. The S&amp;P 500 also rose, gaining, 0.12% to 6,366.84.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46599936/top-2-tech-stocks-you-may-want-to-dump-this-quarter">Top 2 Tech Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Communication services shares jumped by 1% on Thursday.
In trading on Thursday, consumer discretionary stocks dipped by 1.1%.
Top Headline
Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) reported better-than-expected second-quarter financial results and increased its investment in capital expenditures in 2025. Google parent
Alphabet reported second-quarter revenue of $96.43 billion, beating analyst estimates of $93.72 billion. The company reported second-quarter earnings of $2.31 per share, beating estimates of $2.16 per share.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>AEye, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIDR#NASDAQ">LIDR</a>) shares shot up 175% to $3.1100 after the company announced its Apollo lidar has been integrated by NVIDIA into the DRIVE AGX platform.</li>
<li>Shares of West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) got a boost, surging 21% to $275.33 after raising FY25 EPS and sales guidance above estimates.</li>
<li>reAlpha Tech Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) shares were also up, gaining 44% to $0.5157 after the company announced that it has repaid in full the outstanding balance on its secured promissory note with Streeterville Capital.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>LKQ Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>) shares dropped 21% to $30.35 after the company reported worse-than-expected second-quarter adjusted EPS results and cut its FY25 GAAP EPS and adjusted EPS guidance below estimates.</li>
<li>Shares of Sadot Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDOT#NASDAQ">SDOT</a>) were down 29% to $1.11 as the company announced the pricing of public offering.</li>
<li>Community Health Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) was down, falling 30% to $2.7150 following second-quarter results.</li>
</ul>
Commodities In commodity news, oil traded up 1.1% to $66.01 while gold traded down 0.5% at $3,380.00.
Silver traded down 0.5% to $39.310 on Thursday, while copper rose 0.5% to $5.8465.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.24%, while Spain's IBEX 35 Index rose 1.28%. London's FTSE 100 gained 1%, Germany's DAX 40 rose 0.11% and France's CAC 40 fell 0.46% during the session.
Asia Pacific Markets
Asian markets closed mostly higher on Thursday, with Japan's Nikkei 225 surging 1.59%, Hong Kong's Hang Seng gaining 0.51%, China's Shanghai Composite gaining 0.65% and India's BSE Sensex falling 0.66%.
Economics
<ul class="wp-block-list">
<li>The S&amp;P Global manufacturing PMI declined to 49.5 in July, down from market estimates of 52.6.</li>
<li>U.S. initial jobless claims declined by 4,000 from the previous week to 217,000 in the third week of July, compared to market estimates of 227,000.</li>
<li>U.S. building permits fell by 0.1% to an annualized rate of 1.393 million in June.</li>
<li>U.S. natural-gas stocks rose 23 billion cubic feet in the week ending July 18.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46600695/alphabet-to-rally-around-24-here-are-10-top-analyst-forecasts-for-thursday">Alphabet To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Thursday</a></li>
</ul>
Photo via Shutterstock

AIRE

GOOG

GOOGL

LIDR

SDOT

Crude Oil Rises Over 1%; Alphabet Earnings Top Estimates

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Thursday.
Shares of RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) rose sharply on Thursday following better-than-expected <a href="https://www.benzinga.com/quote/RPM/earnings">quarterly EPS and sales.</a>
RPM International reported quarterly earnings of $1.72 per share which beat the analyst consensus estimate of $1.59 per share. The company reported quarterly sales of $2.08 billion which beat the analyst consensus estimate of $2.02 billion.
RPM International shares jumped 10.2% to $124.46 on Thursday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) shares jumped 23.7% to $281.65 after raising FY25 EPS and sales guidance above estimates.</li>
<li>ICON Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) gained 19% to $199.68 after the company reported better-than-expected second-quarter financial results and raised its FY25 sales guidance.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) jumped 18.8% to $31.97 after the company announced its fuel cell technology will be deployed at select Oracle Cloud Infrastructure data centers in the US.</li>
<li>MaxLinear, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) rose 16.6% to $17.87 after the company reported better-than-expected second-quarter sales results and issued third-quarter sales guidance with its midpoint above estimates.</li>
<li>ASGN Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>) gained 16.1% to $58.08 after the company reported better-than-expected quarterly financial results.</li>
<li>Arrive AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAI#NASDAQ">ARAI</a>) rose 15.3% to $11.81.</li>
<li>Solid Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDP#NASDAQ">SLDP</a>) gained 14% to $4.5250.</li>
<li>MicroVision, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) rose 14% to $1.6850.</li>
<li>TMC the metals company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) gained 12.2% to $8.56.</li>
<li>Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) gained 11.4% to $279.00 as the company posted upbeat quarterly results and raised its FY25 forecast.</li>
<li>TechnipFMC plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) gained 10.4% to $37.09 following upbeat quarterly results.</li>
<li>Deutsche Bank Aktiengesellschaft (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>) gained 8.4% to $33.91 after the company reported better-than-expected Q2 sales results.</li>
<li>Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) rose 8.2% to $181.78.</li>
<li>FirstService Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSV#NYSE">FSV</a>) gained 8% to $193.42 following upbeat quarterly results.</li>
<li>Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) gained 6.7% to $94.22 after the company reported better-than-expected second-quarter financial results.</li>
<li>T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) rose 6.7% to $249.90 after the company reported better-than-expected second-quarter earnings.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46570034/jim-cramer-likes-stocks-yield-not-fundamentals">Jim Cramer Loves &#8216;That Yield&#8217; But Passes On This Stock: &#8216;Fundamentals Are Hurting&#8217;</a></li>
</ul>
Photo via Shutterstock

ARAI

ASGN

Laboratory Corporation Of America Holdings

MVIS

NDAQ

SLDP

TMUS

RPM International Posts Better-Than-Expected Earnings, Joins ICON, MaxLinear, Nasdaq And Other Big Stocks Moving Higher On Thursday

West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) shares are surging Thursday after the injectable pharmaceutical packaging and delivery systems company delivered a robust beat on its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46595840/west-announces-second-quarter-2025-results-and-fourth-quarter-2025-dividend-updates-full-year-2025" rel="noreferrer noopener">second-quarter 2025</a> earnings and revenue, while also significantly raising its full-year guidance.
The strong performance was largely driven by exceptional growth in its High-Value Product (HVP) segment, particularly due to strong demand for GLP-1 elastomer products and ongoing momentum in HVP conversions.
The company reported second-quarter 2025 adjusted earnings of $1.84, up from $1.52 a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.51</a>. Similarly, sales reached $766.5 million, outperforming the $726.45 million consensus.
Also Read: <a target="_blank" href="https://www.benzinga.com/node/44994926" rel="noreferrer noopener">West Pharmaceutical Defies Doubters: EPS Jumps,&nbsp;Outlook&nbsp;Raised Despite Tariff Drag</a>
Net sales grew by 9.2%. Organic net sales growth was 6.8%. The Proprietary Products Segment&#8217;s sales increased by 10.7% to $619.8 million and 8.4% organically.
High-Value Product (HVP) (components and devices) represented around 47% of total company net sales and increased 11.3%, driven by strength in Westar and NovaChoice products.
Standard Products, 21% of total company net sales, increased by 0.4%. HVP Delivery Devices&nbsp;represented 13% of total company net sales and increased 30.0%, driven mainly by Daikyo Crystal Zenith and Administration Systems.
The company&#8217;s biologics, pharma, and generics market units each had high-single-digit organic net sales growth.
Contract-manufactured products, representing 19% of total company net sales, increased by 3.0% to $146.7 million, or up 0.5% organically. Segment performance was driven by an increase in sales of self-injection devices for obesity and diabetes, partially offset by a decrease in sales of healthcare diagnostic devices.
On Monday, West Pharmaceutical appointed Robert McMahon as the company&#8217;s new Chief Financial Officer, effective August 4. Mr. McMahon will succeed&nbsp;Bernard Birkett, CFO, who announced his intention to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46513800/west-welcomes-robert-mcmahon-as-incoming-chief-financial-officer" rel="noreferrer noopener">retire earlier this year</a>.
Eric Green, president, CEO and chair of the board, commented, &#8220;I am pleased to report that we exceeded our expectations for the second quarter driven by solid growth in HVP components. This was the result of strong GLP-1 elastomer growth, ongoing momentum in HVP conversion mainly related to Annex 1 projects and the continued normalization of customer ordering patterns. The improved performance was concentrated in higher margin products, which drove strong margin expansion in the quarter.&#8221;
<h2 class="wp-block-heading">Outlook</h2>
West Pharmaceutical Services raised the 2025 adjusted EPS guidance <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44994926/west-pharmaceutical-defies-doubters-eps-jumps-outlook-raised-despite-tariff-drag" rel="noreferrer noopener">from $6.15-$6.35</a> to $6.65-$6.85 compared to the consensus of $6.29.
The company said updated adjusted-diluted EPS guidance incorporates our estimate of $15 to $20 million for the net impact of recently implemented tariffs.
The company raised sales guidance from $2.94 billion-$2.98 billion to&nbsp;$3.04 billion-$3.06 billion&nbsp;versus the consensus of&nbsp;$2.96 billion.
Organic net sales growth is expected to be approximately 3% to 3.75%, up from the previous guidance range of 2% to 3%.
Following the company&#8217;s strong second-quarter 2025 earnings report and raised full-year guidance, William Blair maintained its <a target="_blank" href="https://www.benzinga.com/quote/WST/analyst-ratings" rel="noreferrer noopener">Outperform</a> rating on the stock.
&#8220;The rating is predicated on West being a high-quality, franchise name that provides quality and dependable earnings and cash flow, a clear leadership competitive position, and access to attractive end-market trends without single product or technology risk,&#8221; analyst Matt Larew said on Thursday.
Price Action: WST stock is trading higher by 24.95% to $284.02 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46597552/dow-cuts-dividend-in-half-as-losses-mount-and-tariffs-amplify-industry-pain" target="_blank" rel="noreferrer noopener">Dow Cuts Dividend In Half As Losses Mount And Tariffs Amplify Industry Pain</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Guidance

Health Care

Reiteration

West Pharma Lifts Outlook On Surging GLP-1 Demand, Stock Soars

<h3>Gainers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock moved upwards by 72.8% to $24.2 during Thursday's pre-market session. The market value of their outstanding shares is at $22.1 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock rose 27.08% to $8.22. The company's market cap stands at $170.5 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 25.0% to $0.03. The company's market cap stands at $10.2 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock rose 22.69% to $0.6. The market value of their outstanding shares is at $24.9 million. </li>
<li>West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) stock moved upwards by 22.34% to $278.1. The company's market cap stands at $16.3 billion. As per the press release, Q2 earnings came out today. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>) shares increased by 16.12% to $5.4. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) shares declined by 30.4% to $2.7 during Thursday's pre-market session. The company's market cap stands at $544.3 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) shares declined by 19.21% to $1.43. The market value of their outstanding shares is at $27.2 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock decreased by 14.9% to $1.6. The market value of their outstanding shares is at $10.0 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock declined by 13.94% to $1.05. The company's market cap stands at $6.0 million. </li>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) stock decreased by 10.6% to $0.52. The market value of their outstanding shares is at $45.4 million. </li>
<li>Hyperion DeFi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPD#NASDAQ">HYPD</a>) stock decreased by 9.88% to $8.4. The market value of their outstanding shares is at $47.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADGM

CLSD

CYCC

CYCCP

HYPD

PALI

12 Health Care Stocks Moving In Thursday's Pre-Market Session

WIIM

West Pharmaceutical shares are trading higher after raising FY25 EPS and sales guidance above estimates.

West Pharmaceutical Servs Raises FY2025 GAAP EPS Guidance from $5.86-$6.06 to $6.36-$6.56 vs $6.02 Est

Full-Year 2025 Financial Guidance
<ul>
<li>The Company is increasing its full-year 2025 net sales guidance range to $3.040 billion to $3.060 billion, up from previous guidance of $2.945 billion to $2.975 billion.
<ul>
<li>Net sales guidance includes an estimated full-year 2025 tailwind of approximately $59 million based on current foreign currency exchange rates, compared to previous guidance of a headwind of approximately $5 million.</li>
<li>Organic net sales growth is expected to be approximately 3% to 3.75%, up from the previous guidance range of 2% to 3%.</li>
</ul>
</li>
<li>The Company is increasing its full-year 2025 adjusted-diluted EPS guidance range to $6.65 to $6.85, up from the previous range of $6.15 to $6.35.
<ul>
<li>Full-year adjusted-diluted EPS guidance assumes a $0.27 tailwind based on current foreign exchange rates, compared to previous guidance of no impact.</li>
<li>This guidance includes EPS of $0.04 associated with first-half 2025 tax benefits from stock-based compensation.</li>
<li>Our updated adjusted-diluted EPS guidance incorporates our estimate of $15 to $20 million for the net impact of recently implemented tariffs.</li>
<li>For the remaining quarters of the year, our adjusted-diluted EPS guidance range assumes a tax rate of approximately 21% and does not include potential tax benefits from stock-based compensation. Any tax benefits associated with stock-based compensation beyond those recorded in the first-half of 2025 would provide a positive adjustment to our full-year adjusted-diluted EPS guidance.</li>
</ul>
</li>
<li>Full-year 2025 capital spending guidance is unchanged and is expected to be $275 million.</li>
</ul>

West Pharmaceutical Servs Raises FY2025 Adj EPS Guidance from $6.15-$6.35 to $6.65-$6.85 vs $6.29 Est; Raises FY2025 Sales Guidance from $2.945B-$2.975B to $3.040B-$3.060B vs $2.961B Est

West Pharmaceutical Servs Q2 2025 Adj. EPS $1.84 Beats $1.51 Estimate, Sales $766.500M Beat $726.451M Estimate

ALEX

ALLE

AMAL

AMBP

AMSF

ASPS

BELFA

BELFB

BHLB

BWMX

CIVB

COKE

COLB

COUR

CUBI

DAIO

DCOM

DGICA

DGICB

ENSG

ENVA

FBIZ

FCFS

FFBC

FFIC

FINW

FISI

FLEX

FRST

GBCI

GLPI

HFWA

IBCP

IMAX

INTC

IRDM

ITGR

JAKK

KNSL

LADR

LARK

LBRT

MBLY

MGRC

MOFG

MSBI

MTLS

MYFW

Earnings Scheduled For July 24, 2025

West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) will release its quarterly earnings report on Thursday, 2025-07-24. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate West Pharmaceutical Servs to report an earnings per share (EPS) of $1.51.
Anticipation surrounds West Pharmaceutical Servs's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.22, leading to a 1.88% increase in the share price on the subsequent day.
Here's a look at West Pharmaceutical Servs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.23</td>
<td>1.73</td>
<td>1.50</td>
<td>1.74</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.45</td>
<td>1.82</td>
<td>1.85</td>
<td>1.52</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>8.0%</td>
<td>-7.000000000000001%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753290055_0.png" alt="eps graph" />
<h3>Tracking West Pharmaceutical Servs's Stock Performance</h3>
Shares of West Pharmaceutical Servs were trading at $218.9 as of July 22. Over the last 52-week period, shares are down 18.96%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Insights on West Pharmaceutical Servs</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on West Pharmaceutical Servs.
West Pharmaceutical Servs has received a total of 1 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $245.0, the consensus suggests a potential 11.92% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Illumina, Waters and Medpace Hldgs, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Illumina, with an average 1-year price target of $107.08, suggesting a potential 51.08% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Waters, with an average 1-year price target of $358.2, suggesting a potential 63.64% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Medpace Hldgs, with an average 1-year price target of $412.0, suggesting a potential 88.21% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for Illumina, Waters and Medpace Hldgs, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>West Pharmaceutical Servs</td>
<td>Neutral</td>
<td>0.37%</td>
<td>$231.90M</td>
<td>3.35%</td>
</tr>
<tr>
<td>Illumina</td>
<td>Neutral</td>
<td>-3.25%</td>
<td>$683M</td>
<td>5.53%</td>
</tr>
<tr>
<td>Waters</td>
<td>Neutral</td>
<td>3.90%</td>
<td>$384.96M</td>
<td>6.40%</td>
</tr>
<tr>
<td>Medpace Hldgs</td>
<td>Neutral</td>
<td>8.01%</td>
<td>$178.35M</td>
<td>23.57%</td>
</tr>
</tbody>
</table>

Key Takeaway:
West Pharmaceutical Servs ranks in the middle among its peers for consensus rating. It ranks at the bottom for revenue growth. It is at the top for gross profit. It is at the bottom for return on equity.
<h3>All You Need to Know About West Pharmaceutical Servs</h3>
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
<h3>West Pharmaceutical Servs's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: West Pharmaceutical Servs's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 0.37%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: West Pharmaceutical Servs's net margin excels beyond industry benchmarks, reaching 12.87%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): West Pharmaceutical Servs's ROE excels beyond industry benchmarks, reaching 3.35%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.47%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.11.
<a href="https://www.benzinga.com/quote/WST/earnings">To track all earnings releases for West Pharmaceutical Servs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of West Pharmaceutical Servs's Earnings Potential

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4471431-1&amp;h=1680043096&amp;u=https%3A%2F%2Fwww.westpharma.com%2F&amp;a=West+Pharmaceutical+Services%2C+Inc.">West Pharmaceutical Services, Inc.</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), a global leader in innovative solutions for injectable drug administration, today announced the appointment of Robert McMahon as the company's new Chief Financial Officer (CFO), effective August 4, 2025. Mr. McMahon will succeed&nbsp;Bernard Birkett, CFO, who announced his intention to retire earlier this year. Mr. Birkett will assume the role of Senior Advisor to the CEO through the end of the year to ensure a seamless transition. &nbsp;

Management

West Pharmaceutical Names Robert McMahon as New CFO, Succeeding Retiring Finance Chief Bernard Birkett

Barclays analyst Luke Sergott initiates coverage on West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) with a Equal-Weight rating and announces Price Target of $245.

Initiation

Barclays Initiates Coverage On West Pharmaceutical Servs with Equal-Weight Rating, Announces Price Target of $245

West Pharmaceutical Servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) short percent of float has fallen 10.85% since its last report. The company recently reported that it has 2.25 million shares sold short, which is 4.11% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.54 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>West Pharmaceutical Servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749560432_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for West Pharmaceutical Servs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing West Pharmaceutical Servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, West Pharmaceutical Servs's peer group average for short interest as a percentage of float is 7.41%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About West Pharmaceutical Servs?

West Pharmaceutical Servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) short percent of float has risen 80.08% since its last report. The company recently reported that it has 2.52 million shares sold short, which is 4.61% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.9 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>West Pharmaceutical Servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747339235_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for West Pharmaceutical Servs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing West Pharmaceutical Servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, West Pharmaceutical Servs's peer group average for short interest as a percentage of float is 7.20%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Do Investors Really Feel About West Pharmaceutical Servs?

Despite a powerful 22% surge in the S&amp;P 500 since the April lows—driven by easing U.S.-China trade tensions and a 90-day pause on new tariffs—only half of the index&#8217;s stocks have managed to rise above their 200-day moving average, indicating a market rally <a href="https://www.benzinga.com/movers">that remains potentially incomplete.</a>
This technical indicator, often used to gauge long-term trends and market breadth, currently shows that just 49.9% of S&amp;P 500 components are in what traders would consider a bullish trend. 
That figure remains below both the five- and 10-year averages of 60%, suggesting a wide swath of the market has yet to participate in the rebound.
<h3 class="wp-block-heading">Breadth Gauge Shows Room To Run</h3>
Over the past four years, the percentage of stocks above their 200-day moving average has moved within a wide 10% to 92% range. The extreme lows—seen in June and September 2022 at just 10%—came during periods of heightened recession fears and monetary tightening. 
The recent cycle bottom occurred just last month, when the figure dipped to 15% following April's sharp, tariff-driven selloff.
The highest reading in the last four years came in May 2021, at 92%, during a time of peak post-pandemic optimism. More recently, a high of 82% was recorded in September 2024, following the start of Federal Reserve policy easing. 
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14083211/image-161-1024x529.png" alt="" class="wp-image-914932" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14083211/image-161-1024x529.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14083211/image-161-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14083211/image-161-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14083211/image-161-1536x793.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14083211/image-161-2048x1058.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">What Analysts Say About The Tariff Pause and Market Reaction</h3>
Analysts say that the 90-day tariff truce announced in April and this week&#8217;s truce between the U.S. and China helped revive risk appetite, but they remain cautious about its long-term effects.
In a note on Wednesday, Peter Oppenheimer, strategist at Goldman Sachs, said the outcome was "much better than we had expected," noting that the tariff levies of 30 percentage points by the U.S. and +5 points by China were significantly lower than prior worst-case estimates.
Oppenheimer also highlighted that the new U.S.-UK trade agreement contributes to a more constructive global growth outlook and has mitigated fears of long-term economic damage from the April drawdown.
He added that the market has begun to price out recession risks. 
"Certainly, recent news has been supportive for risk in three respects: it has shown the U.S. Administration to be pragmatic and keen to de-escalate&#8230; it suggests a lower likely outcome for the average effective tariff rate&#8230; and it has led to a number of growth upgrades," he said.
Rick Gardner, chief investment officer at RGA Investments, said markets are already "pricing in an environment where the U.S. and China are able to trade with each other," even if some economic weakness persists.
"Even if we see a continued economic slowdown, the stock market may have already priced that in during the April selloff," Gardner said.
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top 20 Laggards – Price vs. 200-Day Moving Average</h3>
More than 20 S&amp;P 500 stocks are still trading over 20% below their 200-day moving averages, highlighting substantial technical room for recovery among the index's biggest underperformers during the tariff-relief rally. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Company</th>
<th>% Below 200-Day Moving Average</th>
</tr>
</thead>
<tbody>
<tr>
<td>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-42.20%</td>
</tr>
<tr>
<td>Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)</td>
<td>-41.52%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>-30.14%</td>
</tr>
<tr>
<td>Alexandria Real Estate Equities Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>)</td>
<td>-29.88%</td>
</tr>
<tr>
<td>Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>)</td>
<td>-28.40%</td>
</tr>
<tr>
<td>Albemarle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</td>
<td>-27.11%</td>
</tr>
<tr>
<td>IQVIA Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>)</td>
<td>-26.14%</td>
</tr>
<tr>
<td>Bio-Techne Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>)</td>
<td>-24.95%</td>
</tr>
<tr>
<td>Target Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>)</td>
<td>-24.89%</td>
</tr>
<tr>
<td>LyondellBasell Industries N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>)</td>
<td>-24.88%</td>
</tr>
<tr>
<td>Lennar Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>)</td>
<td>-24.48%</td>
</tr>
<tr>
<td>Teradyne Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>)</td>
<td>-24.35%</td>
</tr>
<tr>
<td>West Pharmaceutical Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>)</td>
<td>-24.06%</td>
</tr>
<tr>
<td>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)</td>
<td>-23.67%</td>
</tr>
<tr>
<td>Merck &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>-23.18%</td>
</tr>
<tr>
<td>ON Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)</td>
<td>-23.06%</td>
</tr>
<tr>
<td>Becton, Dickinson and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>)</td>
<td>-22.80%</td>
</tr>
<tr>
<td>Halliburton Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>)</td>
<td>-22.30%</td>
</tr>
<tr>
<td>Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>)</td>
<td>-21.76%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data as of May 13, 2025</figcaption></figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45399438/smci-rated-outperform-by-raymond-james-amid-dominance-in-branded-ai-server-market">SMCI Stock In &#8216;Sweet Spot,&#8217; Says Raymond James — Sets $41 Price Target As AI Revenue Hits 70%</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Large Cap

Economics

BIIB

ENPH

REGN

TECH

Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?

West Pharmaceutical Services, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) on Thursday reported first-quarter 2025 adjusted EPS of $1.45, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.23</a>.
The injectable pharmaceutical packaging and delivery systems company reported sales of $698 million, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44973645/west-announces-first-quarter-2025-results-increases-adjusted-diluted-eps-guidance-and-declares-thi" rel="noreferrer noopener">consensus of $685.84 million</a>.
Net sales grew by 0.6%. Organic net sales growth was 2.4%.
The Proprietary Products Segment&#8217;s sales increased by 0.6% to&nbsp;$563.0 million, and organic <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">net sales growth was 2.4%</a>.
High-value products (components and devices) represented around 73% of segment net sales, led by customer demand for self-injection device platforms partially offset by lower sales of FluroTec products.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44966347/analysts-remain-bullish-on-intuitive-surgical-despite-macro-uncertainty" rel="noreferrer noopener">Analysts Remain Bullish On Intuitive Surgical Despite Macro Uncertainty</a>
<ul>
<li>The Biologics market unit had mid-single-digit organic net sales growth, driven primarily by an increase in sales of self-injection device platforms partially offset by lower sales of FluroTec products.</li>
<li>The Pharma market unit saw mid-single-digit organic net sales growth, driven by increased sales of standard and Westar products.</li>
<li>The Generics market unit had a mid-single-digit decline in organic net sales, driven by a decline in sales of standard and FluroTec products.</li>
</ul>
Contract-Manufactured Products Segment net sales declined by 0.7% to&nbsp;$135.0 million, while organic net sales grew by 0.8%. Segment performance was driven by an increase in sales in self-injection devices for obesity and diabetes, partially offset by a decrease in sales of healthcare diagnostic devices.
On Thursday, West Pharmaceutical said Bernard Birkett, senior vice president and CFO, will step down this year. West has commenced a <a href="https://www.benzinga.com/pressreleases/25/04/n44973904/west-announces-leadership-changes" target="_blank" rel="noreferrer noopener">search for a successor</a>.
Guidance:&nbsp;West Pharmaceutical Services raised the 2025 adjusted EPS <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43704837/west-pharmaceutical-stock-sinks-on-weaker-than-expected-2025-guidance" rel="noreferrer noopener">guidance from $6.00-$6.20</a> to $6.15-$6.35 compared to the consensus of $6.14.
The company raised sales guidance from $2.88 billion-$2.91 billion to $2.94 billion-$2.98 billion vs $2.9 billion.
<ul>
<li>Organic net sales growth is expected to be approximately 2% to 3%.</li>
<li>The company said updated adjusted-diluted EPS guidance incorporates our estimate of&nbsp;$20&nbsp;to&nbsp;$25 million&nbsp;for the net impact of recently implemented tariffs for the remainder of 2025.</li>
</ul>
William Blair analyst Matt Larew writes, &#8220;It appears West has taken proactive measures to address the problems that arose last quarter&#8230;&#8221;
Larew writes that while the increase is primarily due to foreign exchange effects, the solid results are a positive surprise after last quarter&#8217;s weaker outlook, which caused a drop in the stock.
The core business shows signs that inventory issues are improving, demand hasn&#8217;t worsened, and contract manufacturing has grown slightly more than expected.
William Blair maintains <a target="_blank" href="https://www.benzinga.com/quote/WST/analyst-ratings" rel="noreferrer noopener">the Outperform rating</a>.
Price Action: WST stock was down 3.4% at $210.59 on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44981742/nano-cap-briacell-confirms-full-resolution-of-lung-metastasis-in-breast-cancer-trial-stock-shoots-higher" target="_blank" rel="noreferrer noopener">Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher</a></li>
</ul>
Photo: Shutterstock

West Pharmaceutical Defies Doubters: EPS Jumps, Outlook Raised Despite Tariff Drag

Legal

Press Releases

DEADLINE ALERT for WST, DMRC, CODI, and ELV: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

WST Investors Have Opportunity to Lead West Pharmaceutical Services, Inc. Securities Fraud Lawsuit with the Schall Law Firm

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceuticals

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in West Pharmaceutical Services, Inc. of Class Action Lawsuit and Upcoming Deadlines - WST

West Pharmaceutical Services, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before July 7, 2025 to Discuss Your Rights – WST

West to Host Second-Quarter 2025 Conference Call

WEST ALERT: Bragar Eagel & Squire, P.C. is Investigating West Pharmaceutical Services, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

West Welcomes Robert McMahon as Incoming Chief Financial Officer

West Announces Second-Quarter 2025 Results and Fourth-Quarter 2025 Dividend, Updates Full-Year 2025 Guidance

Kuehn Law Encourages Investors of West Pharmaceutical Services, Inc. to Contact Law Firm

CODI

DMRC

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

West Pharmaceutical Servs

West Pharmaceutical Servs (WST) Opciones

West Pharmaceutical Servs (NYSE:WST) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL